Importer of Controlled Substances Application: Fresenius Kabi USA, LLC, 70147-70148 [2021-26677]
Download as PDF
<![CDATA[
70147
Federal Register / Vol. 86, No. 234 / Thursday, December 9, 2021 / Notices
submissions will be available for public
inspection on EDIS.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and in Part 210 of the Commission’s
Rules of Practice and Procedure (19 CFR
part 210).
By order of the Commission.
Issued: December 3, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–26626 Filed 12–8–21; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 701–TA–665 (Final)]
Certain Mobile Access Equipment and
Subassemblies Thereof From China;
Determination
On the basis of the record 1 developed
in the subject investigation, the United
States International Trade Commission
(‘‘Commission’’) determines, pursuant
to the Tariff Act of 1930 (‘‘the Act’’),
that an industry in the United States is
threatened with material injury by
reason of imports of certain mobile
access equipment and subassemblies
thereof (‘‘mobile access equipment’’)
from China, provided for in subheadings
8427.10.80, 8427.20.80, 8427.90.00, and
8431.20.00 of the Harmonized Tariff
Schedule of the United States, that have
been found by the U.S. Department of
Commerce (‘‘Commerce’’) to be
subsidized by the government of China.2
khammond on DSKJM1Z7X2PROD with NOTICES
Background
The Commission instituted this
investigation effective February 26,
2021, following receipt of a petition
filed with the Commission and
Commerce by the Coalition of American
Manufacturers of Mobile Access
Equipment (‘‘CAMMAE’’ or ‘‘the
Coalition’’).3 The Commission
scheduled the final phase of the
investigation following notification of a
preliminary determination by
Commerce that imports of mobile access
equipment from China were being
subsidized within the meaning of
section 703(b) of the Act (19 U.S.C.
1671b(b)). Notice of the scheduling of
the final phase of the Commission’s
investigation and of a public hearing to
1 The record is defined in § 207.2(f) of the
Commission’s Rules of Practice and Procedure (19
CFR 207.2(f)).
2 86 FR 57809 (October 19, 2021).
3 The Coalition is composed of JLG Industries,
Inc. (‘‘JLG’’), Hagerstown, Maryland and Terex
Corporation (‘‘Terex’’), Redmond, Washington.
VerDate Sep<11>2014
17:41 Dec 08, 2021
Jkt 256001
be held in connection therewith was
given by posting copies of the notice in
the Office of the Secretary, U.S.
International Trade Commission,
Washington, DC, and by publishing the
notice in the Federal Register of August
12, 2021 (86 FR 44402). In light of the
restrictions on access to the Commission
building due to the COVID–19
pandemic, the Commission conducted
its hearing through written testimony
and video conference on October 12,
2021. All persons who requested the
opportunity were permitted to
participate.
The Commission made this
determination pursuant to § 705(b) of
the Act (19 U.S.C. 1671d(b)). It
completed and filed its determination in
this investigation on December 3, 2021.
The views of the Commission are
contained in USITC Publication 5242
(December 2021), entitled Certain
Mobile Access Equipment and
Subassemblies Thereof from China:
Investigation No. 701–TA–665 (Final).
By order of the Commission.
Issued: December 3, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–26623 Filed 12–8–21; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–938]
Importer of Controlled Substances
Application: Catalent Pharma
Solutions, LLC
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on September 10, 2021,
Catalent Pharma Solutions LLC, 3031
Red Lion Road, Philadelphia,
Pennsylvania 19114, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
Drug
code
Controlled substance
Psilocybin ......................
Psilocyn .........................
I
7437
7438
Schedule
I
I
I
The company plans to import the
above controlled substances as finished
dosage unit products for clinical trials,
research, and analytical activities. No
other activity for these drug codes is
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Brian S. Besser,
Acting Assistant Administrator.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
[FR Doc. 2021–26678 Filed 12–8–21; 8:45 am]
BILLING CODE P
Catalent Pharma Solutions,
LLC has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 10, 2022. Such
persons may also file a written request
for a hearing on the application on or
before January 10, 2022.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
SUMMARY:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA 937]
Importer of Controlled Substances
Application: Fresenius Kabi USA, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Fresenius Kabi USA, LLC has
applied to be registered as an importer
of basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
SUMMARY:
E:\FR\FM\09DEN1.SGM
09DEN1
70148
Federal Register / Vol. 86, No. 234 / Thursday, December 9, 2021 / Notices
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 10, 2022. Such
persons may also file a written request
for a hearing on the application on or
before January 10, 2022.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
In
accordance with 21 CFR 1301.34(a), this
is notice that on September 8, 2021,
Fresenius Kabi USA, LLC, 3159 Staley
Road, Grand Island, New York 14072–
2028, applied to be registered as an
importer of the following basic class of
controlled substance:
SUPPLEMENTARY INFORMATION:
Drug
code
Controlled substance
Remifentanil ...................
I
9739
Schedule
I II
The company plans to import the
listed controlled substances for bulk
manufacture. No other activity for this
drug code is authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Brian S. Besser,
Acting Assistant Administrator.
khammond on DSKJM1Z7X2PROD with NOTICES
[FR Doc. 2021–26677 Filed 12–8–21; 8:45 am]
Drug Enforcement Administration
[Docket No. DEA–928]
Bulk Manufacturer of Controlled
Substances Application: Noramco
Coventry LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
20:15 Dec 08, 2021
Jkt 256001
these drugs as synthetics. No other
activities for these drug codes are
authorized for this registration.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021–26676 Filed 12–8–21; 8:45 am]
BILLING CODE P
AGENCY:
NATIONAL SCIENCE FOUNDATION
Noramco Coventry LLC, has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplemental Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before February 7, 2022. Such
persons may also file a written request
for a hearing on the application on or
before February 7, 2022.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUMMARY:
In
accordance with 21 CFR 1301.33(a), this
is notice that on September 29, 2021,
Noramco Coventry LLC, 498
Washington Street, Coventry, Rhode
Island 02816, applied to be registered as
a bulk manufacturer of the following
basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug
code
Schedule
Notice of Permits Issued Under the
Antarctic Conservation Act of 1978
National Science Foundation.
Notice of permits issued.
AGENCY:
ACTION:
The National Science
Foundation (NSF) is required to publish
notice of permits issued under the
Antarctic Conservation Act of 1978.
This is the required notice.
FOR FURTHER INFORMATION CONTACT:
Polly Penhale, ACA Permit Officer,
Office of Polar Programs, National
Science Foundation, 2415 Eisenhower
Avenue, Alexandria, VA 22314; 703–
292–8030; email: ACApermits@nsf.gov.
SUPPLEMENTARY INFORMATION: On
November 5, 2021, the National Science
Foundation published a notice in the
Federal Register of permit applications
received. The permits were issued on
December 6, 2021, to:
1. Henry Wulff, Atlas Ocean
Voyages—Permit No. 2022–021
2. Deirdre Dirkman, Vantage Deluxe
World Travel—Permit No. 2022–022
3. Tom Russell, Swan Hellenic
Antarctic—Permit No. 2022–023
4. Michael Hjorth, Albatros
Expeditions—Permit No. 2022–024
SUMMARY:
Erika N. Davis,
Program Specialist, Office of Polar Programs.
[FR Doc. 2021–26671 Filed 12–8–21; 8:45 am]
Marihuana ......................
Tetrahydrocannabinols ..
Dihydromorphine ...........
Methylphenidate ............
Oxycodone ....................
Hydromorphone .............
Hydrocodone .................
Levorphanol ...................
Morphine ........................
Oripavine .......................
Thebaine ........................
Oxymorphone ................
Noroxymorphone ...........
Tapentadol .....................
7360
7370
9145
1724
9143
9150
9193
9220
9300
9330
9333
9652
9668
9780
I
I
I
II
II
II
II
II
II
II
II
II
II
II
The company plans to bulk
manufacture the listed controlled
substances for use as intermediates and
converted to other controlled substances
or for sale to its customers. In reference
to drug codes 7360 (Marihuana), and
7370 (Tetrahydrocannabinols), the
company plans to bulk manufacture
BILLING CODE P
VerDate Sep<11>2014
DEPARTMENT OF JUSTICE
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
BILLING CODE 7555–01–P
NATIONAL SCIENCE FOUNDATION
Notice of Permits Issued Under the
Antarctic Conservation Act of 1978
National Science Foundation.
Notice of permit issued.
AGENCY:
ACTION:
The National Science
Foundation (NSF) is required to publish
notice of permits issued under the
Antarctic Conservation Act of 1978.
This is the required notice.
FOR FURTHER INFORMATION CONTACT:
Polly Penhale, ACA Permit Officer,
Office of Polar Programs, National
Science Foundation, 2415 Eisenhower
Avenue, Alexandria, VA 22314; 703–
292–8030; email: ACApermits@nsf.gov.
SUMMARY:
E:\FR\FM\09DEN1.SGM
09DEN1
]]>Agencies
[Federal Register Volume 86, Number 234 (Thursday, December 9, 2021)]
[Notices]
[Pages 70147-70148]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-26677]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA 937]
Importer of Controlled Substances Application: Fresenius Kabi
USA, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Fresenius Kabi USA, LLC has applied to be registered as an
importer of basic class(es) of controlled substance(s). Refer to
Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and
[[Page 70148]]
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before January 10, 2022.
Such persons may also file a written request for a hearing on the
application on or before January 10, 2022.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on September 8, 2021, Fresenius Kabi USA, LLC, 3159
Staley Road, Grand Island, New York 14072-2028, applied to be
registered as an importer of the following basic class of controlled
substance:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Remifentanil........................... 9739 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
bulk manufacture. No other activity for this drug code is authorized
for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021-26677 Filed 12-8-21; 8:45 am]
BILLING CODE P
